AdvaMed’s six recommendations are:
- · Make innovation in life sciences a priority.
- · Reform the FDA review process.
- · Establish payment policies that support innovation.
- · Change trade policies to provide a level playing field for domestic manufacturing.
- · Implement tax policies that are fair to the device industry.
- · Sustain and improve U.S. research and development.
“We know medical technology has a bright future,” said Stephen Ubl, president and CEO of AdvaMed, in the release. “The question is: Will that future be made in America—or somewhere else?”
Read the AdvaMed release on medical devices.
Related Articles on AdvaMed:
Study: No Safety Benefit Recognized From Slower, Burdensome FDA Approval Process for Devices
Medical Device Group Lobbies Congress on Patient Lawsuits, FDA Approval System
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
